Market news

Investors need to pay close attention to ANIP stock based on the movements in the options market lately.

A number of stocks fell in the afternoon session after sentiment in the healthcare sector weakened, as the Centers for Medicare and Medicaid Services moved to cancel Affordable Care Act coverage for roughly 760,000 people and claw back billions in subsidies.

ANI Pharmaceuticals (NasdaqGM: ANIP) appointed biotechnology executive Henry Gosebruch to its Board of Directors. Gosebruch previously held leadership roles at Lakefront Biotherapeutics, Neumora Therapeutics, and AbbVie. Board member Muthusamy (Samy) Shanmugam resigned from the Board and will continue in key operational roles at ANI Pharmaceuticals. This kind of board refresh is not unique to ANI Pharmaceuticals, and investors who want broader exposure to companies shaped closely by their...

PRINCETON, N.J., Sept. 03, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (ANI or the Company) today announced that Nikhil Lalwani, President and Chief Executive Officer, along with members of the Company’s executive leadership team, will participate in fireside chats at the following upcoming investor conferences: Event2026 Wells Fargo Healthcare Conference DateThursday, September 10, 2026 Time1:30 p.m. ET WebcastClick here EventMorgan Stanley 24th Annual Global Healthcare Co

– Appointment strengthens board as ANI accelerates transformation into a leading Rare Disease Company – PRINCETON, N.J., Aug. 24, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today reported the addition of Henry Gosebruch to its Board of Directors effective August 19, 2026. Mr. Gosebruch brings over 30 years of corporate strategy, business development and finance experience across the biopharmaceutical sector. “We are excited to add Henry to our Board of

ANI Pharmaceuticals’ second quarter was marked by strong year-on-year growth in its rare disease and generics businesses, but the market reacted negatively to the results. Management highlighted the rapid scale-up of its sales force for Cortrophin Gel and robust demand across existing specialties. CEO Nikhil Lalwani noted, “We are seeing significant momentum in demand in the third quarter with July representing the highest month for new cases initiated,” attributing quarterly performance to pers

Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at ANI Pharmaceuticals (NASDAQ:ANIP) and the best and worst performers in the generic pharmaceuticals industry.

Specialty pharmaceutical company ANI Pharmaceuticals (NASDAQ:ANIP) reported Q2 CY2026 results exceeding the market’s revenue expectations, with sales up 25.9% year on year to $266 million. On the other hand, the company’s full-year revenue guidance of $1.11 billion at the midpoint came in 1% below analysts’ estimates. Its non-GAAP profit of $2.21 per share was 8.2% above analysts’ consensus estimates.

ANI (ANIP) delivered earnings and revenue surprises of +9.95% and +1.26%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Specialty pharmaceutical company ANI Pharmaceuticals (NASDAQ:ANIP) reported Q2 CY2026 results topping the market’s revenue expectations, with sales up 25.9% year on year to $266 million. On the other hand, the company’s full-year revenue guidance of $1.11 billion at the midpoint came in 1% below analysts’ estimates. Its non-GAAP profit of $2.21 per share was 8.2% above analysts’ consensus estimates.

Quarterly net revenues of $266.0 million, an increase of 25.9% year-over-yearPurified Cortrophin® Gel net revenues of $117.1 million, an increase of 43.5% year-over-yearQuarterly GAAP net income available to common shareholders of $24.7 million; Quarterly adjusted non-GAAP EBITDA of $71.6 million, an increase of 32.4% year-over-yearDiluted GAAP income per share of $1.05 and adjusted non-GAAP diluted earnings per share of $2.21Reaffirming 2026 guidance for total net revenue of $1,080 - $1,140 mil

ANI Pharmaceuticals (ANIP) Q2 Earnings: What To Expect

From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Those leading the charge have not only realized strong financial performance but also propelled the broader industry’s returns as healthcare stocks have gained 16.6% over the past six months while the S&P 500 was up 7.1%.

ANI (ANIP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

ANI Pharmaceuticals recently reported positive topline results from its Phase 4 SYNCHRONICITY trial of the Fluocinolone Acetonide Intravitreal Implant for chronic non-infectious uveitis affecting the posterior segment, with both 6‑month co-primary endpoints in visual acuity and retinal thickness met in 108 U.S. patients. The data help reinforce the expanded ILUVIEN label for chronic NIU-PS by showing clinically meaningful inflammatory control in a real-world, predominantly older patient...

Ani Pharmaceuticals (ANIP) stock was recently in focus after the company reported statistically significant topline results from its Phase 4 SYNCHRONICITY trial of a fluocinolone acetonide intravitreal implant for chronic non infectious posterior segment uveitis. See our latest analysis for ANI Pharmaceuticals. Despite the positive SYNCHRONICITY data, ANI Pharmaceuticals’ recent share price return has been soft, with the stock down 6.13% over the past month and 1.96% over the past week...

PRINCETON, N.J., July 24, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (ANI or the Company) today announced that the Company will release its second quarter 2026 financial results on Friday, August 7, 2026, at 8:00 a.m. ET. Nikhil Lalwani, President and Chief Executive Officer, Stephen P. Carey, Senior Vice President, Finance, and Chief Financial Officer, and Chris Mutz, Head of Rare Disease will host a webcast and conference call to discuss the results. To view the webcast,

Trial court denied Company’s motion for a new trial and judgment as a matter of law for unjust enrichmentANI intends to appeal rulings to the Delaware Supreme Court and continue to seek to recover the value of the assets it sold to CG Oncology in 2010 PRINCETON, N.J., July 16, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (ANI or the Company) today announced that Judge Sheldon K. Rennie, on July 16, 2026, denied ANI’s post-trial motions for a new trial and judgment as a matte

Carey exercised vested options under a pre-established Rule 10b5-1 trading plan adopted in March, retaining 177,543 directly held shares.

This specialty pharma company, known for its branded and generic drug portfolio, just reported a notable insider sale in the latest filing.